HP 129Xe MRI for Evaluation of CLAD in Lung Transplant Recipients

• Status: Not yet recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the feasibility of hyperpolarized 129Xe MRI in lung transplant recipients and assess structural and functional pulmonary changes using hyperpolarized 129Xe MRI

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: The Hospital for Sick Children
• Collaborator: University Health Network, Toronto
• Treatments: Xenon

Criteria

Inclusion Criteria:

• Patients, deemed clinically stable by the lung transplant team at UHN Toronto Lung Transplant Program (TLTP), 18 years of age or older

• Double lung transplant recipient

• For the 5 CLAD-free participants - at least 1 year of follow-up post-LTx and no substantial and persistent FEV1 decline (as per the ISHLT CLAD definition).

• For the 10 participants with CLAD - prior diagnosis of CLAD made by the clinical team (member of the TLTP).

• PFT measurements within 1 month of scan visit.

• FEV1 > 1.0 L

Exclusion Criteria:

• Currently pregnant or lactating

• Psychiatric or addictive disorders that would preclude obtaining informed consent or adherence to protocol

• Inability to travel to obtain MRI scan

• Any contraindications to MRI including but not limited to severe claustrophobia, implanted devices, aneurysm clips, neurostimulators (patients will be prescreened prior to registration).

• Baseline oxygen saturation of less than 88%.

• Requiring supplemental oxygen at baseline